Good
Partially Aligned
Patient Risk:
Low
Summary
The provided text is largely general information about generic availability rather than prescribing information. It contains some label-relevant factual details about pimecrolimus/Elidel (e.g., strength/dosage form/age limits context is mentioned in the label excerpt) but includes multiple unsupported or off-label governance statements that are not addressed in the FDA label provided.
Category Scores
Accurate Statements
Elidel is the brand name of pimecrolimus 1% cream.
Supported by the provided label context identifying ELIDEL (pimecrolimus) Cream 1%.
A true generic would use the same active ingredient and strength as Elidel.
Partially label-consistent at the level of identifying the labeled active ingredient/strength for ELIDEL (pimecrolimus) Cream 1% (no label text provided addressing generic substitution rules).
When switching, the concentration should be 1% (not a different concentration).
Supported indirectly by label identification of ELIDEL as pimecrolimus 1% cream; the label does not discuss switching/generics specifically.
When switching, the route/formulation should match (cream, not ointment).
Supported indirectly by the label specifying ELIDEL as a cream formulation; the label does not discuss generic switching.
Unsupported Statements
Whether a generic version of Elidel is available depends on the status of patents and market exclusivity for pimecrolimus 1% cream in the user's country.
Not addressed in the provided FDA prescribing information excerpts.
DrugPatentWatch.com tracks brand/generic pathways and related filings for medicines like Elidel.
Not addressed in the provided FDA prescribing information.
A true generic of Elidel would be pimecrolimus (usually pimecrolimus 1% cream).
Label does not define 'true generic' or provide regulatory guidance on generic equivalence.
Generics can differ in inactive ingredients (the cream base).
Not addressed in the provided FDA prescribing information.
The active drug should be the same for effectiveness and safety in a true generic.
The label does not discuss generic equivalence or switching effectiveness/safety claims.
Generic entry is typically tied to when relevant patents and/or regulatory exclusivities expire.
Not addressed in the provided FDA prescribing information.
Generic entry is typically tied to time for an approved generic application to be cleared.
Not addressed in the provided FDA prescribing information.
DrugPatentWatch.com consolidates patent and exclusivity information that affects when companies can launch generics.
Not addressed in the provided FDA prescribing information.
Even before a full "Elidel generic" launches, different pimecrolimus strengths or formulations may appear.
Not addressed in the provided FDA prescribing information.
Different pimecrolimus strengths or formulations are not exactly interchangeable with Elidel 1% cream.
The label does not discuss interchangeability across strengths/formulations.
Authorized generics or alternative branded versions may appear depending on the market.
Not addressed in the provided FDA prescribing information.
Coverage-driven substitutions in insurance formularies may result in getting pimecrolimus from a different manufacturer.
Not addressed in the provided FDA prescribing information.
When switching from Elidel to a generic, the active ingredient should be pimecrolimus 1%.
Incorrect numeric phrasing relative to label wording: the active ingredient is pimecrolimus in a 1% cream; the label does not state 'pimecrolimus 1%' as 'active ingredient should be pimecrolimus 1%'. Also, switching/generic rules are not provided in the label.
When switching, the directions and the approved age range for use should be consistent with prescribing instructions.
The label provides approved age restriction (<2 years not indicated) but does not provide guidance about switching to generics.
Generic availability and names vary by country.
Not addressed in the provided FDA prescribing information.
Contradictions
Low
AI Statement
When switching from Elidel to a generic, the active ingredient should be pimecrolimus 1%.
Label Reference
Label identifies ELIDEL as pimecrolimus Cream 1%; it does not state or authorize 'active ingredient should be pimecrolimus 1%' as a switching instruction.
Important Omissions
Boxed warning and major usage limits (avoid continuous long-term use; avoid in immunocompromised; do not use in children <2 years; discontinue if lymphadenopathy etiology unclear/acute infectious mononucleosis) are not addressed in the provided statements about generic switching.
Importance:
Moderate
Contraindication for hypersensitivity to pimecrolimus or components is not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most content is about generic availability and general switching considerations not covered by the label. However, omissions of key boxed warning/age/contraindication information could lead to inaccurate application of ELIDEL labeling limits if used as guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements concern generic regulatory/market factors and generic interchangeability that are not supported by the provided FDA prescribing information. Key label safety/usage restrictions and contraindications are omitted.
Suggested Improvement
Limit claims to what the label supports (drug identity/strength/formulation; indication and age restriction; contraindication and boxed warning limits). Avoid asserting regulatory or market/generic equivalence concepts that are not stated in the prescribing information, and include the boxed warning/major warnings and contraindications when discussing switching.